ICD-10-PCS › X
ICD-10-PCS codes starting with X
734 codes, page 7 of 8. Every code ever valid for billing is listed, including those now retired.
| Code | Description | Status |
|---|---|---|
| XW043Q9 | Introduction of Posoleucel into Central Vein, Percutaneous Approach, New Technology Group 9 | Valid |
| XW043QB | Introduction of Iloprost into Central Vein, Percutaneous Approach, New Technology Group 11 | Valid |
| XW043R9 | Introduction of Rezafungin into Central Vein, Percutaneous Approach, New Technology Group 9 | Valid |
| XW043RB | Introduction of Letetresgene Autoleucel into Central Vein, Percutaneous Approach, New Technology Group 11 | Valid |
| XW043S5 | Introduction of Iobenguane I-131 Antineoplastic into Central Vein, Percutaneous Approach, New Technology Group 5 | Valid |
| XW043U5 | Introduction of Imipenem-cilastatin-relebactam Anti-infective into Central Vein, Percutaneous Approach, New Technology Group 5 through FY2024 | Retired |
| XW043W5 | Introduction of Caplacizumab into Central Vein, Percutaneous Approach, New Technology Group 5 | Valid |
| XW043WB | Introduction of Fosfomycin Anti-infective into Central Vein, Percutaneous Approach, New Technology Group 11 | Valid |
| XW0534B | Introduction of Somatic Stem Cells into Peripheral Artery, Percutaneous Approach, New Technology Group 11 | Valid |
| XW053T9 | Introduction of Melphalan Hydrochloride Antineoplastic into Peripheral Artery, Percutaneous Approach, New Technology Group 9 | Valid |
| XW0632B | Introduction of CPI-601 Enzyme Replacement Therapy into Cerebral Ventricle, Percutaneous Approach, New Technology Group 11 | Valid |
| XW097M5 | Introduction of Esketamine Hydrochloride into Nose, Via Natural or Artificial Opening, New Technology Group 5 through FY2024 | Retired |
| XW0DX38 | Introduction of Maribavir Anti-infective into Mouth and Pharynx, External Approach, New Technology Group 8 | Valid |
| XW0DX66 | Introduction of Lefamulin Anti-infective into Mouth and Pharynx, External Approach, New Technology Group 6 through FY2025 | Retired |
| XW0DX82 | Introduction of Uridine Triacetate into Mouth and Pharynx, External Approach, New Technology Group 2 | Valid |
| XW0DXF5 | Introduction of Other New Technology Therapeutic Substance into Mouth and Pharynx, External Approach, New Technology Group 5 | Valid |
| XW0DXJ5 | Introduction of Apalutamide Antineoplastic into Mouth and Pharynx, External Approach, New Technology Group 5 through FY2024 | Retired |
| XW0DXJ9 | Introduction of Quizartinib Antineoplastic into Mouth and Pharynx, External Approach, New Technology Group 9 | Valid |
| XW0DXK8 | Introduction of Sabizabulin into Mouth and Pharynx, External Approach, New Technology Group 8 | Valid |
| XW0DXL5 | Introduction of Erdafitinib Antineoplastic into Mouth and Pharynx, External Approach, New Technology Group 5 through FY2024 | Retired |
| XW0DXM6 | Introduction of Baricitinib into Mouth and Pharynx, External Approach, New Technology Group 6 | Valid |
| XW0DXN9 | Introduction of SER-109 into Mouth and Pharynx, External Approach, New Technology Group 9 | Valid |
| XW0DXR5 | Introduction of Venetoclax Antineoplastic into Mouth and Pharynx, External Approach, New Technology Group 5 through FY2024 | Retired |
| XW0DXR7 | Introduction of Fostamatinib into Mouth and Pharynx, External Approach, New Technology Group 7 through FY2026 | Retired |
| XW0DXT5 | Introduction of Ruxolitinib into Mouth and Pharynx, External Approach, New Technology Group 5 through FY2024 | Retired |
| XW0DXV5 | Introduction of Gilteritinib Antineoplastic into Mouth and Pharynx, External Approach, New Technology Group 5 through FY2024 | Retired |
| XW0DXVB | Introduction of Xanomeline and Trospium Chloride into Mouth and Pharynx, External Approach, New Technology Group 11 | Valid |
| XW0E33B | Introduction of Lunsotogene Parvec-cwha via Intracochlear Infusion into Ear(s), Percutaneous Approach, New Technology Group 11 | Valid |
| XW0G738 | Introduction of Maribavir Anti-infective into Upper GI, Via Natural or Artificial Opening, New Technology Group 8 | Valid |
| XW0G7K8 | Introduction of Sabizabulin into Upper GI, Via Natural or Artificial Opening, New Technology Group 8 | Valid |
| XW0G7M6 | Introduction of Baricitinib into Upper GI, Via Natural or Artificial Opening, New Technology Group 6 | Valid |
| XW0G7R7 | Introduction of Fostamatinib into Upper GI, Via Natural or Artificial Opening, New Technology Group 7 through FY2026 | Retired |
| XW0G886 | Introduction of Mineral-based Topical Hemostatic Agent into Upper GI, Via Natural or Artificial Opening Endoscopic, New Technology Group 6 | Valid |
| XW0H738 | Introduction of Maribavir Anti-infective into Lower GI, Via Natural or Artificial Opening, New Technology Group 8 | Valid |
| XW0H7K8 | Introduction of Sabizabulin into Lower GI, Via Natural or Artificial Opening, New Technology Group 8 | Valid |
| XW0H7M6 | Introduction of Baricitinib into Lower GI, Via Natural or Artificial Opening, New Technology Group 6 | Valid |
| XW0H7R7 | Introduction of Fostamatinib into Lower GI, Via Natural or Artificial Opening, New Technology Group 7 through FY2026 | Retired |
| XW0H7X8 | Introduction of Broad Consortium Microbiota-based Live Biotherapeutic Suspension into Lower GI, Via Natural or Artificial Opening, New Technology Group 8 | Valid |
| XW0H886 | Introduction of Mineral-based Topical Hemostatic Agent into Lower GI, Via Natural or Artificial Opening Endoscopic, New Technology Group 6 | Valid |
| XW0J3HA | Introduction of Paclitaxel-Coated Balloon Technology, One Balloon into Coronary Artery, One Artery, Percutaneous Approach, New Technology Group 10 | Valid |
| XW0J3JA | Introduction of Paclitaxel-Coated Balloon Technology, Two Balloons into Coronary Artery, One Artery, Percutaneous Approach, New Technology Group 10 | Valid |
| XW0J3KA | Introduction of Paclitaxel-Coated Balloon Technology, Three Balloons into Coronary Artery, One Artery, Percutaneous Approach, New Technology Group 10 | Valid |
| XW0J3LA | Introduction of Paclitaxel-Coated Balloon Technology, Four or More Balloons into Coronary Artery, One Artery, Percutaneous Approach, New Technology Group 10 | Valid |
| XW0K3HA | Introduction of Paclitaxel-Coated Balloon Technology, One Balloon into Coronary Artery, Two Arteries, Percutaneous Approach, New Technology Group 10 | Valid |
| XW0K3JA | Introduction of Paclitaxel-Coated Balloon Technology, Two Balloons into Coronary Artery, Two Arteries, Percutaneous Approach, New Technology Group 10 | Valid |
| XW0K3KA | Introduction of Paclitaxel-Coated Balloon Technology, Three Balloons into Coronary Artery, Two Arteries, Percutaneous Approach, New Technology Group 10 | Valid |
| XW0K3LA | Introduction of Paclitaxel-Coated Balloon Technology, Four or More Balloons into Coronary Artery, Two Arteries, Percutaneous Approach, New Technology Group 10 | Valid |
| XW0L3HA | Introduction of Paclitaxel-Coated Balloon Technology, One Balloon into Coronary Artery, Three Arteries, Percutaneous Approach, New Technology Group 10 | Valid |
| XW0L3JA | Introduction of Paclitaxel-Coated Balloon Technology, Two Balloons into Coronary Artery, Three Arteries, Percutaneous Approach, New Technology Group 10 | Valid |
| XW0L3KA | Introduction of Paclitaxel-Coated Balloon Technology, Three Balloons into Coronary Artery, Three Arteries, Percutaneous Approach, New Technology Group 10 | Valid |
| XW0L3LA | Introduction of Paclitaxel-Coated Balloon Technology, Four or More Balloons into Coronary Artery, Three Arteries, Percutaneous Approach, New Technology Group 10 | Valid |
| XW0M3HA | Introduction of Paclitaxel-Coated Balloon Technology, One Balloon into Coronary Artery, Four or More Arteries, Percutaneous Approach, New Technology Group 10 | Valid |
| XW0M3JA | Introduction of Paclitaxel-Coated Balloon Technology, Two Balloons into Coronary Artery, Four or More Arteries, Percutaneous Approach, New Technology Group 10 | Valid |
| XW0M3KA | Introduction of Paclitaxel-Coated Balloon Technology, Three Balloons into Coronary Artery, Four or More Arteries, Percutaneous Approach, New Technology Group 10 | Valid |
| XW0M3LA | Introduction of Paclitaxel-Coated Balloon Technology, Four or More Balloons into Coronary Artery, Four or More Arteries, Percutaneous Approach, New Technology Group 10 | Valid |
| XW0Q316 | Introduction of Eladocagene exuparvovec into Cranial Cavity and Brain, Percutaneous Approach, New Technology Group 6 | Valid |
| XW0Q35C | Introduction of Ifezuntirgene Inilparvovec into Cranial Cavity and Brain, Percutaneous Approach, New Technology Group 12 | Valid |
| XW0U0CC | Introduction of Recombinant Human Bone Morphogenetic Protein-2 with Collagen Scaffold into Joints, Open Approach, New Technology Group 12 | Valid |
| XW0U0GA | Introduction of Vancomycin Hydrochloride and Tobramycin Sulfate Anti-Infective, Temporary Irrigation Spacer System into Joints, Open Approach, New Technology Group 10 | Valid |
| XW0U0XB | Introduction of Peptide Enhanced Bone Void Filler into Joints, Open Approach, New Technology Group 11 | Valid |
| XW0U3XB | Introduction of Peptide Enhanced Bone Void Filler into Joints, Percutaneous Approach, New Technology Group 11 | Valid |
| XW0U4XB | Introduction of Peptide Enhanced Bone Void Filler into Joints, Percutaneous Endoscopic Approach, New Technology Group 11 | Valid |
| XW0V0BC | Introduction of Vancomycin-eluting Bone Void Filler into Bones, Open Approach, New Technology Group 12 | Valid |
| XW0V0P7 | Introduction of Gentamicin-eluting Bone Void Filler into Bones, Open Approach, New Technology Group 7 | Valid |
| XW0V3WA | Introduction of AGN1 Bone Void Filler into Bones, Percutaneous Approach, New Technology Group 10 | Valid |
| XW1 | New Technology, Anatomical Regions, Transfusion | Not billable |
| XW13325 | Transfusion of Convalescent Plasma (Nonautologous) into Peripheral Vein, Percutaneous Approach, New Technology Group 5 | Valid |
| XW1337A | Transfusion of Marnetegragene Autotemcel into Peripheral Vein, Percutaneous Approach, New Technology Group 10 | Valid |
| XW133B8 | Transfusion of Betibeglogene Autotemcel into Peripheral Vein, Percutaneous Approach, New Technology Group 8 | Valid |
| XW133C8 | Transfusion of Omidubicel into Peripheral Vein, Percutaneous Approach, New Technology Group 8 | Valid |
| XW133D7 | Transfusion of High-Dose Intravenous Immune Globulin into Peripheral Vein, Percutaneous Approach, New Technology Group 7 through FY2026 | Retired |
| XW133E7 | Transfusion of Hyperimmune Globulin into Peripheral Vein, Percutaneous Approach, New Technology Group 7 | Valid |
| XW133F8 | Transfusion of OTL-103 into Peripheral Vein, Percutaneous Approach, New Technology Group 8 through FY2026 | Retired |
| XW133G8 | Transfusion of Atidarsagene Autotemcel into Peripheral Vein, Percutaneous Approach, New Technology Group 8 | Valid |
| XW133H9 | Transfusion of Lovotibeglogene Autotemcel into Peripheral Vein, Percutaneous Approach, New Technology Group 9 | Valid |
| XW133J8 | Transfusion of Exagamglogene Autotemcel into Peripheral Vein, Percutaneous Approach, New Technology Group 8 | Valid |
| XW133SB | Transfusion of Mozafancogene Autotemcel into Peripheral Vein, Percutaneous Approach, New Technology Group 11 | Valid |
| XW133YB | Transfusion of Nonautologous (Human) Fibrinogen Concentrate, Shelf-stable into Peripheral Vein, Percutaneous Approach, New Technology Group 11 | Valid |
| XW14325 | Transfusion of Convalescent Plasma (Nonautologous) into Central Vein, Percutaneous Approach, New Technology Group 5 | Valid |
| XW1437A | Transfusion of Marnetegragene Autotemcel into Central Vein, Percutaneous Approach, New Technology Group 10 | Valid |
| XW143B8 | Transfusion of Betibeglogene Autotemcel into Central Vein, Percutaneous Approach, New Technology Group 8 | Valid |
| XW143C8 | Transfusion of Omidubicel into Central Vein, Percutaneous Approach, New Technology Group 8 | Valid |
| XW143D7 | Transfusion of High-Dose Intravenous Immune Globulin into Central Vein, Percutaneous Approach, New Technology Group 7 through FY2026 | Retired |
| XW143E7 | Transfusion of Hyperimmune Globulin into Central Vein, Percutaneous Approach, New Technology Group 7 | Valid |
| XW143F8 | Transfusion of Etuvetidigene Autotemcel into Central Vein, Percutaneous Approach, New Technology Group 8 | Valid |
| XW143G8 | Transfusion of Atidarsagene Autotemcel into Central Vein, Percutaneous Approach, New Technology Group 8 | Valid |
| XW143H9 | Transfusion of Lovotibeglogene Autotemcel into Central Vein, Percutaneous Approach, New Technology Group 9 | Valid |
| XW143J8 | Transfusion of Exagamglogene Autotemcel into Central Vein, Percutaneous Approach, New Technology Group 8 | Valid |
| XW143SB | Transfusion of Mozafancogene Autotemcel into Central Vein, Percutaneous Approach, New Technology Group 11 | Valid |
| XW143YB | Transfusion of Nonautologous (Human) Fibrinogen Concentrate, Shelf-stable into Central Vein, Percutaneous Approach, New Technology Group 11 | Valid |
| XW2 | New Technology, Anatomical Regions, Transfusion through FY2021 | Retired |
| XW23346 | Transfusion of Brexucabtagene Autoleucel Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 6 through FY2021 | Retired |
| XW23376 | Transfusion of Lisocabtagene Maraleucel Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 6 through FY2021 | Retired |
| XW24346 | Transfusion of Brexucabtagene Autoleucel Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 6 through FY2021 | Retired |
| XW24376 | Transfusion of Lisocabtagene Maraleucel Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 6 through FY2021 | Retired |
| XWH | New Technology, Anatomical Regions, Insertion | Not billable |
| XWHD7Q7 | Insertion of Neurostimulator Lead into Mouth and Pharynx, Via Natural or Artificial Opening, New Technology Group 7 | Valid |
| XX2 | New Technology, Physiological Systems, Monitoring | Not billable |
| XX20X89 | Monitoring of Brain Electrical Activity, Computer-aided Detection and Notification, New Technology Group 9 | Valid |
| XX25X0A | Monitoring of Blood Flow, Adhesive Ultrasound Patch Technology, New Technology Group 10 | Valid |